Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-22-007708
Filing Date
2022-01-12
Accepted
2022-01-12 16:30:31
Documents
1
Group Members
BLACKSTONE CLARUS III L.L.C.BLACKSTONE GROUP MANAGEMENT L.L.C.BLACKSTONE HOLDINGS I/II GP L.L.C.BLACKSTONE HOLDINGS II L.P.BLACKSTONE INC.CLARUS VENTURES III GP, L.P.STEPHEN A. SCHWARZMAN

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d236904dsc13da.htm SC 13D/A 147074
  Complete submission text file 0001193125-22-007708.txt   148897
Mailing Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142 617-949-2200
Clarus Lifesciences III, L.P. (Filed by) CIK: 0001597143 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1214
Type: SC 13D/A

Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Subject) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: SC 13D/A | Act: 34 | File No.: 005-88939 | Film No.: 22526901
SIC: 2834 Pharmaceutical Preparations